( LOS ANGELES--(BUSINESS WIRE)--May 21 2...)Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at AUA Annual Meeting,Health

LOS ANGELES--(BUSINESS WIRE)--May 21, 2007 - Cougar Biotechnology, Inc. (OTCBB:CGRB) today announced that positive Phase I and Phase II data on the Company's prostate cancer drug candidate CB7630 (abiraterone acetate) was presented at the American Urological Association (AUA) Annual Meeting, which is currently taking place in Anaheim, California. The data was presented by Dr. Timothy A. Yap from the Cancer Research UK Centre for Cancer Therapeutics at The Institute of Cancer Research in an oral presentation entitled, "Abiraterone acetate, an inhibitor of androgen synthesis, has significant antitumor activity in castration resistant prostate cancer."

The Phase I/II trial of CB7630 was conducted at The Institute of Cancer Research and at The Royal Marsden NHS Foundation Trust in the United Kingdom. In the trial, CB7630 was administered orally, once daily, to chemotherapy-naive patients with castration refractory prostate cancer (CRPC), who had progressive disease despite treatment with LHRH analogues and multiple other hormonal therapies, including antiandrogens, diethylstilboestrol and dexamethasone. To date a total of 38 patients have been treated in the Phase I/II trial, including 15 patients treated in the Phase I portion of the trial and 23 patients treated in the Phase II portion of the trial. In his presentation, Dr. Yap reported that in the 38 patients treated in this trial, CB7630 was well tolerated at doses as high as 2000 mg/day with minimal toxicity. Moreover, no dose limiting toxicity has been observed in the trial to date.

In the 30 patients who were evaluable in the Phase I/II trial, 18 patients (60%) experienced a confirmed decline in prostate specific antigen (PSA) levels of greater than 50%, with 10 of the 30 patients (33%) experiencing PSA declines of greater than 90%. Six additional patients (20%) experienced a decline in PSA that was less than 50%. Of the 20 evaluable patients with mea
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
2. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ASCO Annual Meeting
3. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
4. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
7. Prana Biotechnology Presents New Key Findings on PBT2
8. Generex Biotechnology Vaccine Strategy Presented at International Conference in London
9. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
10. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis